Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details rather than financial performance metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the acquisition of GSK Ordinary Shares by specific individuals following the re-investment of dividends paid on January 8, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of share transactions.
Important Facts for Investors
- Transaction Date: January 9, 2015.
- Share Price: 1415.84 pence per Share.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Directors and Connected Persons Involved:
- Sir Andrew Witty (Director): 4,319 shares.
- Lady C Witty (Connected person of Sir Andrew Witty): 2,076 shares.
- Mr I W Whyte (Connected person of Mrs V A Whyte): 274 shares.